Company intelligence / Profile preview

EM Perry Group

United Kingdom or United States*linkedin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

EM Perry Group appears to be a small consultancy owned by Emily Perry focusing on start-up strategy and operations. It does not operate within the life science/biotech/pharma/healthcare space according to all publicly available data[4]. No additional corporate structure details—such as website presence or employee count—are currently accessible.

Industry: Consulting

Drug pipeline

3 assets

zelenectide pevedotin

Phase 2/3

Indications: Metastatic urothelial cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on EM Perry Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EM Perry Group.

Explore the full profile